孕烷X受体在乳腺癌耐药中的研究进展

doi:10.3760/cma.j.cn371439-20240422-00098

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (9): 590-594.doi: 10.3760/cma.j.cn371439-20240422-00098

孕烷X受体在乳腺癌耐药中的研究进展

韩晓旭¹, 张楠²(), 刘帅²()

¹bobapp1中国有限公司研究生部，济南 250117
²bobapp1中国有限公司附属中心医院乳腺疾病诊疗中心，济南 250013

收稿日期:2024-04-22 修回日期:2024-05-07 出版日期:2024-09-08 发布日期:2024-10-12
通讯作者: 张楠,刘帅 E-mail:zlkzn2016@126.com;discoveryliu@163.com
基金资助:
山东省自然科学基金(ZR2020MH201);山东省医学会临床科研资金——齐鲁专项(YXH2022ZX02168);济南市卫生健康委员会大数据科技计划(2022-YBD-03)

Progress in the study of the pregnane X receptor in drug resistance in breast cancer

Han Xiaoxu¹, Zhang Nan²(), Liu Shuai²()

¹School of Graduate， Shandong First Medical University， Jinan 250117， China
²Breast Centre， Central Hospital Affiliated to Shandong First Medical University， Jinan 250013， China

Received:2024-04-22 Revised:2024-05-07 Online:2024-09-08 Published:2024-10-12
Contact: Zhang Nan, Liu Shuai E-mail:zlkzn2016@126.com;discoveryliu@163.com
Supported by:
Natural Science Foundation of Shandong Province of China(ZR2020MH201);Clinical Research Foundation of Shandong Medical Association—Qilu Special Project(YXH2022ZX02168);Big Data Technology Plan of Jinan Municipal Health Commission(2022-YBD-03)

摘要/Abstract

摘要：

孕烷X受体（PXR）是细胞色素P-450表达的关键调节因子，参与氧化应激、类固醇和胆汁酸代谢、炎症反应、细胞凋亡、细胞增殖等多种生物学行为，还参与化疗药物的代谢、运输和清除。PXR激活后可通过遗传变异与表观遗传修饰、调节细胞凋亡以及参与磷酸化/去磷酸化等途径影响乳腺癌化疗药物耐药，可能是乳腺癌耐药患者潜在的治疗靶点。

关键词: 乳腺肿瘤, 孕烷X受体, 抗药性

Abstract:

The pregnane X receptor （PXR） is a crucial regulator of cytochrome P-450 （CYP450） expression. It is involved in oxidative stress， steroid and bile acid metabolism， inflammatory response， apoptosis， cell proliferation and other biological behaviors， and also participates in the metabolism， transport and clearance of chemotherapy drugs. After activation， PXR can affect chemotherapy drug resistance of breast cancer through genetic variation and epigenetic modification， regulation of apoptosis， and participation in phosphorylation/dephosphorylation. It may be a potential therapeutic target for patients with breast cancer resistance.

Key words: Breast neoplasms, Pregnane X receptor, Drug resistance

韩晓旭, 张楠, 刘帅. 孕烷X受体在乳腺癌耐药中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 590-594.

Han Xiaoxu, Zhang Nan, Liu Shuai. Progress in the study of the pregnane X receptor in drug resistance in breast cancer[J]. Journal of International Oncology, 2024, 51(9): 590-594.

参考文献 38

[1]	Kashyap D, Pal D, Sharma R, et al. Global increase in breast cancer incidence: risk factors and preventive measures[J]. Biomed Res Int, 2022, 2022: 9605439. DOI: 10.1155/2022/9605439.
[2]	何思怡, 李贺, 曹毛毛, 等. 全球及我国女性乳腺癌疾病负担年龄分布及变化趋势[J]. 中国肿瘤, 2023, 32(1): 1-7. DOI: 10.11735/j.issn.1004-0242.2023.01.A001.
[3]	Niu X, Wu T, Li G, et al. Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance[J]. Int J Biol Sci, 2022, 18(2): 742-759. DOI: 10.7150/ijbs.68724. pmid: 35002522
[4]	Skandalaki A, Sarantis P, Theocharis S. Pregnane X receptor (PXR) polymorphisms and cancer treatment[J]. Biomolecules, 2021, 11(8): 1142. DOI: 10.3390/biom11081142.
[5]	Rao ZZ, Tang ZW, Wen J. Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor[J]. World J Clin Oncol, 2023, 14(9): 335-342. DOI: 10.5306/wjco.v14.i9.335.
[6]	Dai Y, Luo J, Xiang E, et al. Prenatal exposure to retrorsine induces developmental toxicity and hepatotoxicity of fetal rats in a sex-dependent manner: the role of pregnane X receptor activation[J]. J Agric Food Chem, 2021, 69(10): 3219-3231. DOI: 10.1021/acs.jafc.0c06748.
[7]	Wang HB, Chu F, Zhang XF, et al. TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs[J]. Cell Death Dis, 2023, 14(1): 64. DOI: 10.1038/s41419-022-05537-7.
[8]	Kamaraj R, Drastik M, Maixnerova J, et al. Allosteric antagonism of the pregnane X receptor (PXR): current-state-of-the-art and prediction of novel allosteric sites[J]. Cells, 2022, 11(19): 2974. DOI: 10.3390/cells11192974.
[9]	Matheux A, Gassiot M, Fromont G, et al. PXR modulates the prostate cancer cell response to afatinib by regulating the expression of the monocarboxylate transporter SLC16A1[J]. Cancers (Basel), 2021, 13(14): 3635. DOI: 10.3390/cancers13143635.
[10]	Rigalli JP, Theile D, Nilles J, et al. Regulation of PXR function by coactivator and corepressor proteins: ligand binding is just the beginning[J]. Cells, 2021, 10(11): 3137. DOI: 10.3390/cells10113137.
[11]	Sári Z, Mikó E, Kovács T, et al. Indolepropionic acid, a metabolite of the microbiome, has cytostatic properties in breast cancer by activating AHR and PXR receptors and inducing oxidative stress[J]. Cancers (Basel), 2020, 12(9): 2411. DOI: 10.3390/cancers12092411.
[12]	Shao Z, Li Y, Dai W, et al. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR[J]. Pharmacol Res, 2018, 135: 188-200. DOI: 10.1016/j.phrs.2018.08.003. pmid: 30114438
[13]	Yang H, Ren L, Wang Y, et al. FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis[J]. Cell Death Dis, 2020, 11(10): 851. DOI: 10.1038/s41419-020-03053-0.
[14]	Sun J, Pang MD, Tang XZ, et al. Anti-tumor effect of gambogenic acid and its effect on CYP2C and CYP3A after oral administration[J]. Chem Pharm Bull (Tokyo), 2023, 71(5): 334-341. DOI: 10.1248/cpb.c22-00656. pmid: 36858593
[15]	Qiao EQ, Yang HJ, Yu XF, et al. Curcuma zedoaria petroleum ether extract reverses the resistance of triple-negative breast cancer to docetaxel via pregnane X receptor[J]. Ann Transl Med, 2021, 9(17): 1389. DOI: 10.21037/atm-21-4199.
[16]	Wen J, Lv Z, Ding H, et al. Association between PXR polymorphisms and cancer risk: a systematic review and meta-analysis[J]. Biosci Rep, 2018, 38(3): BSR20171614. DOI: 10.1042/BSR20171614.
[17]	Revathidevi S, Sudesh R, Vaishnavi V, et al. Screening for the 3'UTR polymorphism of the PXR gene in South Indian breast cancer patients and its potential role in pharmacogenomics[J]. Asian Pac J Cancer Prev, 2016, 17(8): 3971-3977.
[18]	Li Y, Zhou Y, Mao F, et al. miR-452 reverses abnormal glycosy-lation modification of ERα and estrogen resistance in TNBC (triple-negative breast cancer) through targeting UGT1A1[J]. Front Oncol, 2020, 10: 1509. DOI: 10.3389/fonc.2020.01509.
[19]	Theocharis S, Giaginis C, Gourzi S, et al. High pregnane X receptor (PXR) expression is correlated with poor prognosis in invasive breast carcinoma[J]. Diagnostics (Basel), 2021, 11(11): 1946. DOI: 10.3390/diagnostics11111946.
[20]	Li T, Kong A, Ma Z, et al. Protein arginine methyltransferase 1 may be involved in pregnane x receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistant[J]. Oncotarget, 2016, 7(15): 20236-20248. DOI: 10.18632/oncotarget.7752. pmid: 26934120
[21]	Sultana H, Kato A, Ohashi A, et al. Effect of vitamin K-mediated PXR activation on drug-metabolizing gene expression in human intestinal carcinoma LS180 cell line[J]. Nutrients, 2021, 13(5): 1709. DOI: 10.3390/nu13051709.
[22]	Madejczyk AM, Canzian F, Góra-Tybor J, et al. Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia[J]. Front Oncol, 2022, 12: 952640. DOI: 10.3389/fonc.2022.952640.
[23]	Gautam S, Singh P, Singh M, et al. Rifaximin, a pregnane X receptor (PXR) activator regulates apoptosis in a murine model of breast cancer[J]. RSC Adv, 2018, 8(7): 3512-3521. DOI: 10.1039/c7ra09689e.
[24]	Oladimeji PO, Wright WC, Wu J, et al. RNA interference screen identifies NAA10 as a regulator of PXR transcription[J]. Biochem Pharmacol, 2019, 160: 92-109. DOI: 10.1016/j.bcp.2018.12.012. pmid: 30566892
[25]	Jiang Y, Feng D, Ma X, et al. Pregnane X receptor regulates liver size and liver cell fate by yes-associated protein activation in mice[J]. Hepatology, 2019, 69(1): 343-358. DOI: 10.1002/hep.30131. pmid: 30048004
[26]	Xing YQ, Yan J, Niu YD. PXR: a center of transcriptional regulation in cancer[J]. Acta Pharm Sin B, 2020, 10(2): 197-206. DOI: 10.1016/j.apsb.2019.06.012. pmid: 32082968
[27]	Yan L, Chen Z, Wu L, et al. Inhibitory effect of PXR on ammonia-induced hepatocyte autophagy via P53[J]. Toxicol Lett, 2018, 295: 153-161. DOI: 10.1016/j.toxlet.2018.06.1066. pmid: 29908302
[28]	Ming WH, Luan ZL, Yao Y, et al. Pregnane X receptor activation alleviates renal fibrosis in mice via interacting with p53 and inhibiting the Wnt7a/β-catenin signaling[J]. Acta Pharmacol Sin, 2023, 44(10): 2075-2090. DOI: 10.1038/s41401-023-01113-7.
[29]	Rosenthal SB, Bush KT, Nigam SK. A network of SLC and ABC transporter and DME genes involved in remote sensing and signaling in the gut-liver-kidney axis[J]. Sci Rep, 2019, 9(1): 11879. DOI: 10.1038/s41598-019-47798-x.
[30]	Hammer H, Schmidt F, Marx-Stoelting P, et al. Cross-species analysis of hepatic cytochrome P450 and transport protein expression[J]. Arch Toxicol, 2021, 95(1): 117-133. DOI: 10.1007/s00204-020-02939-4. pmid: 33150952
[31]	Fritz A, Busch D, Lapczuk J, et al. Expression of clinically relevant drug-metabolizing enzymes along the human intestine and their correlation to drug transporters and nuclear receptors: an intra-subject analysis[J]. Basic Clin Pharmacol Toxicol, 2019, 124(3): 245-255. DOI: 10.1111/bcpt.13137.
[32]	van Eijk M, Boosman RJ, Schinkel AH, et al. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes[J]. Cancer Chemother Pharmacol, 2019, 84(3): 487-499. DOI: 10.1007/s00280-019-03905-3.
[33]	Kumar H, Gupta NV, Jain R, et al. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer[J]. J Adv Res, 2023, 54: 271-292. DOI: 10.1016/j.jare.2023.02.005.
[34]	Nabekura T, Kawasaki T, Jimura M, et al. Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glyco-protein[J]. Biochem Biophys Rep, 2020, 21: 100727. DOI: 10.1016/j.bbrep.2020.100727.
[35]	Bhagyaraj E, Ahuja N, Kumar S, et al. TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR[J]. Cell Cycle, 2019, 18(24): 3589-3602. DOI: 10.1080/15384101.2019.1693120. pmid: 31739702
[36]	Li Y, Lin W, Chai SC, et al. Design and optimization of 1H-1,2,3-triazole-4-carboxamides as novel, potent, and selective inverse agonists and antagonists of PXR[J]. J Med Chem, 2022, 65(24): 16829-16859. DOI: 10.1021/acs.jmedchem.2c01640.
[37]	Finamore C, Festa C, Fiorillo B, et al. Expanding the library of 1,2,4-oxadiazole derivatives: discovery of new farnesoid X receptor (FXR) antagonists/pregnane X receptor (PXR) agonists[J]. Molecules, 2023, 28(6): 2840. DOI: 10.3390/molecules2806 2840.
[38]	Mustonen EK, Pantsar T, Rashidian A, et al. Target hopping from protein kinases to PXR: identification of small-molecule protein kinase inhibitors as selective modulators of pregnane X receptor from TüKIC library[J]. Cells, 2022, 11(8): 1299. DOI: 10.3390/cells11081299.

孕烷X受体在乳腺癌耐药中的研究进展

Progress in the study of the pregnane X receptor in drug resistance in breast cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孟繁明. 伊尼妥单抗联合卡培他滨治疗曲妥珠单抗经治的HER2阳性晚期乳腺癌1例[J]. 国际肿瘤学杂志, 2024, 51(8): 538-541.
[2]	赵彪, 蒲琴, 袁美芳, 马立双, 李瀚, 杨毅, 孙朝细. 基于内缘切线野的调强放疗与容积弧形调强放疗在左侧乳腺癌保乳术后放疗中的剂量学研究[J]. 国际肿瘤学杂志, 2024, 51(7): 441-447.
[3]	刘琴, 张强强, 杨继元, 胡艳. 晚期前列腺癌双侧乳腺和腋窝淋巴结转移1例[J]. 国际肿瘤学杂志, 2024, 51(7): 478-480.
[4]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[5]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[6]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[7]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[8]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[9]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[10]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[11]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[12]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[13]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[14]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[15]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.